- Home
- RCKT vs CLLS Comparison
RCKT vs CLLS Comparison
Compare RCKT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RCKT | CLLS |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.6M | 374.2M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | RCKT | CLLS |
|---|---|---|
| Price | $4.97 | $3.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 2 |
| Target Price | ★ $30.27 | $8.50 |
| AVG Volume (30 Days) | ★ 1.9M | 31.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | N/A | $20.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.19 | $1.10 |
| 52 Week High | $9.42 | $5.48 |
Technical Indicators
Market Signals| Indicator | RCKT | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 83.21 | 47.45 |
| Support Level | $2.99 | $3.41 |
| Resistance Level | $8.26 | $4.54 |
| Average True Range (ATR) | 0.26 | 0.18 |
| MACD | 0.17 | 0.05 |
| Stochastic Oscillator | 83.30 | 51.76 |
Price Performance
Historical ComparisonAbout RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.